Markets:

Overview

News

Currencies

International

Treasuries

Roundhill GLP-1 & Weight Loss ETF (NQ:OZEM)

30.61 -0.22 (-0.71%)

Official Closing Price Updated: 4:15 PM EDT, Apr 28, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Roundhill GLP-1 & Weight Loss ETF

3 Ways to Invest in the Growing GLP-1 Weight Loss Market ↗

April 17, 2026

Via MarketBeat

Eli Lilly’s Diabetes Pill Outperforms Oral Semaglutide in Phase 3 Trial ↗

February 26, 2026

Investors are closely watching the oral GLP-1 race as competition intensifies across the sector.

Via Stocktwits

Novo, Vivtex Ink $2.1 Billion Deal To Develop Oral Medicines For Obesity And Diabetes ↗

February 25, 2026

Novo Nordisk will lead global development, regulatory approval, manufacturing, and commercialization of the resulting products.

Via Stocktwits

Novo Looks To Ireland To Scale Production Of Wegovy Pill: Report ↗

February 12, 2026

Via Stocktwits

Hoth Therapeutics's GDNF Treatment Shows Superior Efficacy Over Wegovy, Ozempic In Preclinical Trial ↗

February 10, 2026

The company announced positive preclinical results from a study evaluating GDNF as a potential treatment for obesity and metabolic-associated steatotic liver disease.

Via Stocktwits

Why Wegovy Maker Novo Nordisk’s Stock Is Sliding 3% Premarket Today ↗

September 29, 2025

Via Stocktwits

HIMS New $49 Pill Lifts Stock 10%, But Why Are NVO, LLY Stocks Falling? ↗

February 05, 2026

The company announced the launch of a compounded copy of the Wegovy weight-loss pill at an introductory price of $49 per month.

Via Stocktwits

Topics Intellectual Property

Novo Awaits FDA Call On Higher-Dose Wegovy In Early 2026 – NVO Stock Extends Decline Pre-Market On Weak Guidance ↗

February 04, 2026

Novo Nordisk submitted a supplemental New Drug Application (NDA) to the FDA in November, and under the CNPV program, a review decision is usually expected within one to two months after the filing is...

Via Stocktwits

Topics Intellectual Property

LLY Stock Surges Pre-Market: Obesity, Diabetes Drugs Drive Strong FY26 Outlook ↗

February 04, 2026

Fourth-quarter revenue surged 43% to $19.3 billion, above Street estimates of $17.86 billion, according to Fiscal.ai data.

Via Stocktwits

Ozempic, Mounjaro, Wegovy, or Zepbound? This ETF Holds Them All ↗

January 19, 2026

Via MarketBeat

Topics ETFs

Eli Lilly Extends Lead In $150B Obesity Drug Race As Novo, Pfizer Clash — Here's How ETFs Stand To Gain ↗

October 30, 2025

As Eli Lilly, Novo Nordisk, and Pfizer battle for dominance in the obesity-drug market, these ETFs are offering exposure to the GLP-1 gold rush.

Via Benzinga

Topics ETFs

Are You Making These 3 ETF Mistakes That Cost You 50% in Gains? ↗

October 13, 2025

Exchange-traded funds are great long-term investments, but you have to think about them in the right way.

Via The Motley Fool

Topics ETFs

Eli Lilly's Blockbuster Obesity Drugs Miss Sales Estimates Again, But Investors Cheer Q4 Earnings Beat ↗

February 06, 2025

Older diabetes medicines outperformed expectations, helping offset the shortfall in Lilly’s newer treatments.

Via Stocktwits

Eli Lilly Gets Wall Street Backing After Tuesday’s Turmoil, Stock Rises Premarket As Retail Stays Bullish ↗

January 15, 2025

JPMorgan's Chris Schott reportedly called the stock dip following the Q4 sales miss a buying opportunity.

Via Stocktwits

Topics Earnings

Eli Lilly Stock Faces Worst Day In Nearly 4 Years On Q4 Weight-Loss Drug Sales Miss, But Retail Bullish On 2025 Projections ↗

January 14, 2025

The pharma giant expects continued growth for Mounjaro and Zepbound this year, supported by expanded manufacturing capacity and new market launches.

Via Stocktwits

Topics Earnings

Eli Lilly Stock Soars 34.42% YTD: A $1000 Investment Outpaces Returns From These ETFs Holding Mounjaro-Maker Shares ↗

December 13, 2024

Recently, the company announced a massive $15 billion share buyback plan and a 15% dividend increase.

Via Benzinga

Topics ETFs

EXCLUSIVE: Weight-Loss Duopoly Breaks As Eli Lilly, Novo Plummet; 'Market Won't Be Dominated By Just 2 Players' ↗

July 18, 2024

Eli Lilly and Novo Nordisk face selloff as new weight-loss drugs threaten dominance. Shares of both companies drop significantly, highlighting need for diversification in this industry.

Via Benzinga

ETFs Bet High On Weight Loss Drugs, But Industry Observers Question Long-Term Potential ↗

June 07, 2024

New ETFs focusing on weight-loss drugs have launched. However, industry observers caution about their long-term prospects and the concentrated risks associated with these investments.

Via Benzinga

Topics ETFs

New Weight Loss ETF Is Essentially A Play On Eli Lilly, Novo Nordisk ↗

May 30, 2024

New OZEM ETF offers investors exposure to weight-loss sector through top pharmaceutical companies Eli Lilly and Novo Nordisk, with potential for high growth but also risks.

Via Benzinga

Topics ETFs

Tesla (TSLA) Stock Drops as Glass Lewis Urges Against Elon Musk’s Pay Package ↗

May 28, 2024

Tesla stock is down on Tuesday as advisory firm Glass Lewis recommends TSLA shareholders vote against a massive pay package for Elon Musk.

Via InvestorPlace

Campbell Soup Layoffs 2024: What to Know About New Campbell Job Cuts ↗

May 28, 2024

Campbell Soup layoffs are coming for 415 workers as the company plans to close down one factory and shift operations at others.

Via InvestorPlace

Topics Workforce

OZEM ETF: 7 Things to Know About the New Roundhill GLP-1 & Weight Loss ETF ↗

May 28, 2024

As weight loss drugs are gaining popularity Roundhill GLP 1 And Weight Loss ETF (OZEM) has launched as anew way to invest in them.

Via InvestorPlace

Topics ETFs

South Park Took On Crypto, AI Previously: Animated Comedy Targets Weight-Loss Drug Ozempic Next ↗

May 23, 2024

Weight loss drugs get the new parody treatment in a "South Park" streaming special.

Via Benzinga

Topics Artificial Intelligence

EXCLUSIVE: Roundhill Investments Launches Weight Loss ETF For Exposure To Blockbuster Drugs Like Ozempic ↗

May 21, 2024

Roundhill CEO Dave Mazza says investors "can't just buy a basket of big pharma names or a broad-based biotech ETF and call it a day."

Via Benzinga

Topics ETFs

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.